Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analyses
- PMID: 36458114
- PMCID: PMC9706604
- DOI: 10.1016/j.omtm.2022.11.003
Assessing production variability in empty and filled adeno-associated viruses by single molecule mass analyses
Abstract
Adeno-associated viruses (AAVs) are useful vehicles for gene therapy because of their stability, low immunogenicity. and non-pathogenicity. However, disparity in AAV sample preparations (e.g., in capsid composition, DNA packaging, and impurities) gives rise to product heterogeneity, with possibly undesired effects on gene delivery. Ideally, AAV production should be with full control of AAV structure and genetic payload. Therefore, robust, efficient, and low material consuming methods are essential to characterize AAVs. Here, we use two emerging single-molecule techniques, mass photometry and Orbitrap-based charge-detection mass spectrometry, and show how they may efficiently and accurately characterize AAVs. We were able to resolve heterogeneous pools of particles, evaluating AAVs from two different serotypes (AAV8 and AAV2), produced by three independent production platforms, either lacking a genome or packed with a transgene. Together our data confirm that the different AAV production methods result in rather different and diverse AAV particle distributions. Especially for the packed AAVs, frequently additional subspecies were observed, next to the expected packed genome, mostly resulting from under- or overpackaging of genome material and/or residual empty particles. This work further establishes that both these single-particle techniques may become valuable tools in characterizing AAVs before they are used in gene therapy.
Keywords: AAV biomanufacturing; AAV2; AAV8; Adeno-associated virus; charge-detection mass spectrometry; empty-filled ratio; gene-delivery vector; mass photometry; native mass spectrometry; single molecule mass analyses.
© 2022 The Author(s).
Conflict of interest statement
A.R., M.N., and M.T. are employees of Roche Diagnostics GmbH, Penzberg, Germany, a company with interest in using AAV vectors for gene-delivery purposes.
Figures





Similar articles
-
Probing recombinant AAV capsid integrity and genome release after thermal stress by mass photometry.Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101293. doi: 10.1016/j.omtm.2024.101293. eCollection 2024 Sep 12. Mol Ther Methods Clin Dev. 2024. PMID: 39100914 Free PMC article.
-
Assessment of genome packaging in AAVs using Orbitrap-based charge-detection mass spectrometry.Mol Ther Methods Clin Dev. 2021 Nov 29;24:40-47. doi: 10.1016/j.omtm.2021.11.013. eCollection 2022 Mar 10. Mol Ther Methods Clin Dev. 2021. PMID: 34977271 Free PMC article.
-
Quantification of Empty, Partially Filled and Full Adeno-Associated Virus Vectors Using Mass Photometry.Int J Mol Sci. 2023 Jul 3;24(13):11033. doi: 10.3390/ijms241311033. Int J Mol Sci. 2023. PMID: 37446211 Free PMC article.
-
Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.Hum Gene Ther Methods. 2016 Feb;27(1):1-12. doi: 10.1089/hgtb.2015.140. Hum Gene Ther Methods. 2016. PMID: 26757051 Free PMC article. Review.
-
Adeno-Associated Virus (AAV) - Based Gene Therapies for Retinal Diseases: Where are We?Appl Clin Genet. 2023 May 30;16:111-130. doi: 10.2147/TACG.S383453. eCollection 2023. Appl Clin Genet. 2023. PMID: 37274131 Free PMC article. Review.
Cited by
-
Therapeutic Application and Structural Features of Adeno-Associated Virus Vector.Curr Issues Mol Biol. 2024 Aug 2;46(8):8464-8498. doi: 10.3390/cimb46080499. Curr Issues Mol Biol. 2024. PMID: 39194716 Free PMC article. Review.
-
Dissecting the structural heterogeneity of proteins by native mass spectrometry.Protein Sci. 2023 Apr;32(4):e4612. doi: 10.1002/pro.4612. Protein Sci. 2023. PMID: 36851867 Free PMC article. Review.
-
Production and characterization of an AAV1-VP3-only capsid: An analytical benchmark standard.Mol Ther Methods Clin Dev. 2023 May 9;29:460-472. doi: 10.1016/j.omtm.2023.05.002. eCollection 2023 Jun 8. Mol Ther Methods Clin Dev. 2023. PMID: 37273903 Free PMC article.
-
AAV yield, bioactivity, and particle heterogeneity are impacted by genome size and non-coding DNA elements.Mol Ther Methods Clin Dev. 2025 Jun 2;33(3):101499. doi: 10.1016/j.omtm.2025.101499. eCollection 2025 Sep 11. Mol Ther Methods Clin Dev. 2025. PMID: 40590037 Free PMC article.
-
Stochastic assembly of biomacromolecular complexes: impact and implications on charge interpretation in native mass spectrometry.Chem Sci. 2023 Aug 17;14(35):9316-9327. doi: 10.1039/d3sc03228k. eCollection 2023 Sep 13. Chem Sci. 2023. PMID: 37712025 Free PMC article.
References
-
- Sha S., Maloney A.J., Katsikis G., Nguyen T.N.T., Neufeld C., Wolfrum J., Barone P.W., Springs S.L., Manalis S.R., Sinskey A.J., et al. Cellular pathways of recombinant adeno-associated virus production for gene therapy. Biotechnol. Adv. 2021;49:107764. - PubMed
-
- Li C., Samulski R.J. Engineering adeno-associated virus vectors for gene therapy. Nat. Rev. Genet. 2020;21:255–272. - PubMed
-
- Wu Z., Asokan A., Samulski R.J. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Mol. Ther. 2006;14:316–327. - PubMed
-
- Girod A., Wobus C.E., Zádori Z., Ried M., Leike K., Tijssen P., Kleinschmidt J.A., Hallek M. The VP1 capsid protein of adeno-associated virus type 2 is carrying a phospholipase A2 domain required for virus infectivity. J. Gen. Virol. 2002;83:973–978. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources